18F-AV-45 PET Imaging of Amyloid in PD with Cognitive Impairment

Award Information
Department of Health and Human Services
Solitcitation Year:
Solicitation Number:
Award Year:
Phase I
Agency Tracking Number:
Solicitation Topic Code:
Small Business Information
AVID RADIOPHARMACEUTICALS, INC., 3624 Market Street, 5th Floor, Philadelphia, PA, 19104
Hubzone Owned:
Woman Owned:
Socially and Economically Disadvantaged:
Principal Investigator
 (215) 966-6208
Business Contact
Phone: (215) 966-6208
Email: skovronsky@avidrp.com
Research Institution
DESCRIPTION (provided by applicant): Dementia associated with PD (PDD) is common (affecting up to 80% of patients long-term) and highly disabling. Informative biomarkers are urgently needed to understand the pathology of PDD, to improve the early detection of cognitive deficits and to facilitate the development of treatments for PDD. Nuclear imaging technologies have the potential to produce such biomarkers. Numerous studies have used 11C-PIB to measure amyloid burden in Alzheimer's disease (AD) and other d ementing illnesses. However, the experience with amyloid imaging in PD has been limited, in spite of post-mortem evidence for substantial amyloid deposition in patients with PD. One of the impediments to conducting additional studies with 11C-PIB has been the short half life of 11C (H20 min), necessitating an on-site cyclotron and in-house radiochemistry expertise. Since the PET isotope 18F has a 110 minute half life and a well established nationwide distribution network, it has been our long standing corpo rate goal to develop an 18F amyloid imaging agent for amyloid plaques. We have recently developed and validated in human trials such an agent, 18F-AV-45, which is easy to use, can be made cheaply and reliably, and can be distributed on a regional basis. Mo st importantly, the compound shows an excellent ability (as good as or better than 11C-PIB) to image amyloid plaques in Alzheimer's disease. In this STTR grant we propose to conduct the first ever clinical trial of 18F-AV-45 in PD patients. The over-archin g aim of this study is to use 18F-AV-45 imaging of amyloid burden as a biomarker to test the relationship between amyloid burden and cognitive functioning in PD. We will image 25 PD subjects over 2 years with 18F-AV-45 and will compare imaging results with clinical data and CSF biomarkers (tau and a-beta) of amyloid pathology. We hypothesize that 18F-AV-45 binding will be associated with greater degrees of overall cognitive impairment, shorter interval between onset of motor and cognitive impairment, and pa ttern of CSF biomarkers reflecting amyloid pathology. PUBLIC HEALTH RELEVANCE: Successful validation of amyloid imaging as a biomarker for cognitive impairment in Parkinson's disease (PD) would represent a significant milestone in improving the diagnosis a nd treatment of this highly disabling feature of PD, and would represent a significant commercial opportunity for molecular imaging of these patients. However, little information is currently available regarding the amyloid burden, as measured by molecular imaging, in patients with PD or dementia associated with PD (PDD). 18F-AV- 45 is a fluorinated PET isotope that has favorable properties and has been shown to accurately identify amyloid pathology in Alzheimer's patients. In this project, we propose to us e 18F-AV-45 to image amyloid pathology in patients with PD with cognitive impairment for the first time. Avid Radiopharmaceuticals is an experienced leader in developing new commercial PET tracers and is collaborating with world-experts on cognitive impair ment in PD to conduct this clinical trial of amyloid imaging in PD and PDD.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government